Effect of Intravenous Infusion of Lidocaine on Patients Undergoing Radical Resection of Colorectal Tumors

Affiliated Hospital of Nantong University

Status: Completed

Conditions: Lidocaine; Colorectal Tumors

Treatments: Drug: Administer 1.5 mg/kg intravenously to the patient before induction of anesthesia, and continue to infuse 1.5 mg/kg/h during the operation until the end of the operation

Study type: Interventional

Funder types: Other

Identifiers

NCT05484687

MA2021008

Details and patient eligibility

About

Colorectal cancer (CRC) is one of the most common malignant tumors in the world. Surgical resection is the main treatment option for colorectal cancer patients. Surgery may enhance or accelerate tumor recurrence and metastasis. Multiple factors in the tumor microenvironment play important roles in tumor recurrence and metastasis, and modulating the tumor microenvironment can inhibit disease progression. Lidocaine has been found to inhibit tumor growth in animal experiments.

Full description

Lidocaine was applied in the operation of colorectal tumor patients, and the effect on the postoperative microenvironment and micrometastasis of the patients was observed by detecting the stress, immunity, vascular tumor regeneration, inflammation, etc. of the patients.

Enrollment: 100 patients

Sex: All

Ages: 30 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• colorectal tumor patients

Exclusion criteria

• Weight <45kg and >100kg
• Sensitivity or hypersensitivity to lidocaine
• Second or third degree heart block
• Severe heart failure (ejection fraction < 20%)
• History of active rhythm disorder
• Acute severe liver and kidney injury
• History of uncontrolled seizures
• History of acute porphyria.

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

Lidocaine is used in radical resection of colorectal tumors.

Experimental group

Description:

Administer 1.5 mg/kg intravenously to the patient before induction of anesthesia, and continue to infuse 1.5 mg/kg/h during the operation until the end of the operation

Treatment:

Drug: Administer 1.5 mg/kg intravenously to the patient before induction of anesthesia, and continue to infuse 1.5 mg/kg/h during the operation until the end of the operation